Keros Therapeutics (NASDAQ:KROS) Coverage Initiated at Guggenheim

Guggenheim began coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report issued on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $96.00 price target on the stock. Guggenheim’s price target points to a potential upside of 72.04% from the company’s previous close.

A number of other equities analysts have also commented on the stock. Truist Financial reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Bank of America reduced their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Oppenheimer started coverage on Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $90.63.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $55.80 on Monday. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -10.83 and a beta of 1.22. Keros Therapeutics has a 1-year low of $27.02 and a 1-year high of $73.00. The business has a 50-day moving average of $49.53 and a 200-day moving average of $52.97.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The firm had revenue of $0.04 million during the quarter. During the same period last year, the business earned ($1.27) earnings per share. Research analysts expect that Keros Therapeutics will post -4.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares in the company, valued at approximately $5,260,163.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 22.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC acquired a new stake in shares of Keros Therapeutics during the fourth quarter worth $27,367,000. Redmile Group LLC acquired a new stake in shares of Keros Therapeutics during the 1st quarter worth approximately $36,576,000. Darwin Global Management Ltd. boosted its position in Keros Therapeutics by 35.4% during the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after purchasing an additional 375,523 shares during the period. Franklin Resources Inc. grew its stake in Keros Therapeutics by 47.9% during the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after buying an additional 226,674 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after buying an additional 176,803 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.